Novartis and PTC Partner on Potential First Oral Huntington’s Disease Therapy
hope on the Horizon: Novartis and PTC Team Up to Develop Potential Breakthrough Huntington’s Disease treatment
New York, NY – In a major advancement for the Huntington’s disease community, Novartis pharmaceuticals Corporation has announced a groundbreaking collaboration with PTC Therapeutics to develop a potential first-in-class oral therapy for this devastating neurodegenerative disorder.
The global license and collaboration agreement focuses on PTC Therapeutics’ promising drug candidate, PTC518. Under the terms of the deal, PTC will receive an upfront payment of $1 billion, with the potential to earn up to an additional $1.9 billion based on achieving key development, regulatory, and sales milestones.
“This collaboration combines PTC’s expertise in developing small molecule splicing therapies with Novartis’s expertise in global development and commercialization of neuroscience therapies,” said Dr. Matthew Klein, Chief Executive Officer of PTC Therapeutics. “We are excited to collaborate with Novartis to accelerate the potential of PTC518 for the hundreds of thousands of Huntington’s disease patients worldwide in need of a therapy designed to be well-tolerated and an effective disease-modifying therapy.”
PTC518 is currently being evaluated in the ongoing Phase II PIVOT-HD trial. Interim results released in June showed promising signs, demonstrating a durable, dose-dependent reduction in mutant Huntingtin protein levels in both blood and cerebrospinal fluid after 12 months of treatment.
“PTC518 is the leading oral disease-modifying therapy in development for Huntington’s disease and the economics of this agreement are consistent with the promise of this treatment,” Dr. Klein added.
Under the agreement, Novartis will be responsible for the development, manufacturing, and commercialization of PTC518, which is an HTT mRNA splice modulator. The license agreement is expected to close in the first quarter of 2025, subject to customary closing conditions.
This collaboration represents a significant step forward in the fight against Huntington’s disease, offering renewed hope for patients and their families. PTC, a biopharmaceutical company focused on developing therapies for rare disorders, has a proven track record of innovation, having previously developed Evrysdi® (risdiplam), the first-ever approved small molecule splicing modifier.
With Novartis’s global reach and expertise, PTC518 has the potential to become a transformative treatment option for individuals living with Huntington’s disease.
A New Dawn for huntington’s Disease? Novartis and PTC Team Up on Potential Breakthrough
NewsDirectory3.com – In a move that has energized teh Huntington’s disease community, pharmaceutical giants Novartis and PTC Therapeutics announced a landmark collaboration aimed at developing a groundbreaking oral treatment for this devastating neurodegenerative disorder.
The collaboration centers around PTC Therapeutics’ investigational drug candidate, PTC518, an oral HTT mRNA splice modulator.Initial findings from the ongoing Phase II PIVOT-HD trial have shown promising results, revealing a notable and sustainable reduction in mutant Huntingtin protein levels in both blood and cerebrospinal fluid after 12 months of treatment.
“This collaboration merges PTC’s expertise in developing small molecule splicing therapies with Novartis’ prowess in global progress and commercialization of neuroscience therapies,” stated Dr. Matthew klein, CEO of PTC Therapeutics.
Under the agreement, PTC Therapeutics will receive an upfront payment of $1 billion, with the potential for up to $1.9 billion in additional payments contingent upon achieving key developmental milestones,regulatory approvals,and sales targets.
Dr.Klein underscored the significance of PTC518, stating, “PTC518 is currently the leading oral disease-modifying therapy in development for Huntington’s disease, and the economics of this agreement reflect the promise this treatment holds.”
Novartis will assume responsibility for the development, manufacturing, and commercialization of PTC518, leveraging its extensive global network and experience. The licensing agreement is expected to be finalized in the first quarter of 2025.
This collaboration represents a major stride forward in the battle against HuntingtonS disease, offering renewed hope for patients and their families worldwide.